Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab
Inflammatory Bowel Diseases · 02.07.2026
DOI: 10.1093/ibd/izag139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 02.07.2026. Verfasst von Joyce Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
There are limited data regarding the impact of body mass index (BMI) on pharmacokinetics in patients with inflammatory bowel disease (IBD) treated with vedolizumab (VDZ) or ustekinumab (UST). The aim of the study was to investigate the association of BMI with VDZ and UST concentrations in IBD.
Methods
This single-center, retrospective study included consecutive patients with IBD who received intravenous (iv) VDZ or UST and underwent therapeutic drug monitoring (TDM) from November 2016 to March 2023. We assessed the correlation of BMI with drug concentrations using Spearman’s rank test.
Results
The study population consisted of 170 patients; 89 (52%) patients received iv VDZ [44% Crohn’s disease (CD)] and 81 received UST (81% CD). There was an inverse correlation of baseline BMI [ρ: −0.321; 95% confidence interval (CI) −0.534 to −0.070; P = .011] and BMI at first TDM (ρ: −0.253; 95% CI, −0.462 to −0.018; P = .031) with UST concentration at first TDM. Regarding the latter, subgroup analyses revealed that this correlation referred only to patients with Crohn’s disease (CD) (ρ: −0.293; 95% CI, −0.515 to −0.035; P = .023) or patients with IBD on standard UST dosing (ρ: −0.369; 95% CI, −0.616 to −0.055; P = .019). In contrast, there was no correlation of BMI with VDZ concentrations. Multivariable linear regression analysis identified higher BMI at first TDM as an independent variable associated with lower UST concentrations (B: −0.408; 95% CI, −0.930 to −0.217; P = .002).
Conclusion
This study demonstrated an inverse correlation between BMI and UST concentrations in patients with CD or patients with IBD on standard UST dosing, suggesting the need for closer TDM and dose adjustments to ensure optimal drug exposure in these patients with higher BMI.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
- Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
ORCID-Profile: Konstantinos Papamichael
Zitieren
APA
Lee, J., Porth, R., Saraga, A., Gade, A., Deyhim, T., Soliman, M., Moini, S. H., Zullow, S., Rabinowitz, L., Grossberg, L., Cheifetz, A. S., & Papamichael, K. (2026). Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag139
Vancouver
Lee J, Porth R, Saraga A, Gade A, Deyhim T, Soliman M, et al. Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag139
BibTeX
@article{Lee2026,
author = {Lee, Joyce and Porth, Rachel and Saraga, Alessandra and Gade, Ajay and Deyhim, Tina and Soliman, Mostafa and Moini, Sadra Habibi and Zullow, Samantha and Rabinowitz, Loren and Grossberg, Laurie and Cheifetz, Adam S and Papamichael, Konstantinos},
title = {Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag139}
}
EUVIMED